Product Description
Abametapir is a novel pediculicidal metalloproteinase inhibitor used to treat infestations of head lice. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Abametapir)
Mechanisms of Action: Metalloproteinase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | United States
Approved Indications: None
Company: Hatchtech Pty
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Lice Infestations|Mite Infestations
Phase 2: Mite Infestations|Lice Infestations
Phase 1: Erythema|Edema|Lice Infestations|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02062073 |
Ha03-006 | P1 |
Completed |
Healthy Volunteers |
2014-03-01 |
2020-04-30 |
Primary Endpoints|Treatments |
|
NCT02061813 |
Ha03-007 | P1 |
Completed |
Erythema|Edema |
2014-01-01 |
2021-07-27 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT01518699 |
Ha02-005 | P1 |
Completed |
Lice Infestations |
2012-05-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
ACTRN12607000014459 |
Ha01-001 | P1 |
Completed |
Healthy Volunteers |
None |
2026-02-15 |
Treatments |
|
NCT02097485 |
Ha03-008 | P2 |
Completed |
Mite Infestations|Lice Infestations |
2014-09-01 |
2020-05-02 |
||
NCT02010333 |
Ha03-003 | P2 |
Completed |
Mite Infestations|Lice Infestations |
2014-07-01 |
2020-05-13 |
Primary Endpoints|Treatments |
|
NCT01907490 |
Ha03-004 | P2 |
Completed |
Mite Infestations|Lice Infestations |
2013-07-01 |
2020-04-29 |
Primary Endpoints|Treatments |
|
NCT01336647 |
Ha02-003 | P2 |
Completed |
Lice Infestations |
2011-08-01 |
2020-04-30 |
Primary Endpoints|Treatments |
|
NCT02062060 |
Ha03-002 | P3 |
Completed |
Mite Infestations|Lice Infestations |
2014-07-01 |
2020-05-13 |
Primary Endpoints|Treatments |
|
NCT02060903 |
Ha03-001 | P3 |
Completed |
Lice Infestations|Mite Infestations |
2014-07-01 |
2020-05-13 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/14/2026 |
News Article |
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium |
|
03/31/2026 |
News Article |
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain |
|
03/12/2026 |
News Article |
Pelthos Therapeutics to Present at 38th Annual ROTH Conference |
|
03/09/2026 |
News Article |
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 |